# Immunitas Therapeutics

> Immunitas Therapeutics, Inc. is a Boston, Massachusetts clinical-stage biotechnology company
> developing novel antibody therapeutics for cancer and autoimmune disease. It has no public API,
> no developer portal, and no machine-readable API contract. This file is generated by API
> Evangelist from a third-party profile of the company's public surface; it is not published by
> Immunitas Therapeutics.

generated: 2026-08-23
method: generated
source: apis.yml + probes recorded in well-known/immunitas-therapeutics-well-known.yml

## What this company is

- Clinical-stage biotech, founded on single-cell analysis of the tumor microenvironment.
- Founding science came from Dana-Farber Cancer Institute, Mass General Cancer Center, the Broad
  Institute and MIT; the team identified CD161 (KLRB1) as a T-cell target, published in Cell (2021).
- Lead program IMT-009, an anti-CD161 antibody, is in a Phase 1/2a dose-escalation and expansion
  study in advanced solid tumors and hematological malignancies, including a Phase 1b combination
  with fruquintinib in microsatellite-stable colorectal cancer.
- A second, preclinical anti-CD161 program (IMT-380) for chronic inflammatory / autoimmune disease
  was licensed to Boehringer Ingelheim in May 2026.
- Completed a $58M Series B in August 2021.

## API surface

There is none, and this is an honest zero rather than a gap in our search. Probed 2026-08-23:

- https://www.immunitastx.com/openapi.json — 404
- https://www.immunitastx.com/openapi.yaml — 404
- https://www.immunitastx.com/swagger.json — 404
- https://www.immunitastx.com/api-docs — 404
- https://www.immunitastx.com/.well-known/agent-card.json — 404
- https://www.immunitastx.com/.well-known/api-catalog — 404
- https://www.immunitastx.com/.well-known/security.txt — 404
- https://www.immunitastx.com/llms.txt — 404
- https://www.immunitastx.com/sitemap.xml — 200, four URLs, none developer-facing

No GraphQL endpoint, MCP server, A2A agent card, gRPC service or WSDL was found on any host the
company controls.

## Open source software (the one machine-consumable thing published)

- GitHub organization: https://github.com/immunitastx
- monkeybread — https://pypi.org/project/monkeybread/ — `pip install monkeybread`
  Python library for analyzing cellular niches in single-cell spatial transcriptomics data.
  MIT licensed, "Copyright (c) 2022, Immunitas Therapeutics". Latest release 1.0.3 (2023-08-23).
  Docs: https://monkeybread.readthedocs.io/ · Source: https://github.com/immunitastx/monkeybread
- monkeybread-case-study, recover-counts, NSCLS-PIC, terra-docker — source-only research code,
  not distributed through any package registry.

## Links

- Website: https://www.immunitastx.com/
- Contact: info@immunitastx.com — https://www.immunitastx.com/home#contact
- Privacy Policy: https://www.immunitastx.com/privacy-policy
- Terms and Conditions: https://www.immunitastx.com/terms-and-conditions
- LinkedIn: https://www.linkedin.com/company/immunitas/

## If you are an agent looking for an integration point

Stop here. Immunitas Therapeutics sells therapeutics, not software. The only programmable artifact
it publishes is the monkeybread Python package above, which is a local analysis library — it calls
no Immunitas service and requires no credentials.